Inclusion Criteria:

- Patients with radically resected adenocarcinoma of the stomach and/or
gastroesophageal junction with histologic proof of adenocarcinoma, pathologically
staged T2-3, any N, M0

- No prior radiation therapy to the stomach or immunotherapy or chemotherapy for any
reason

- Patients must have a life expectancy of at least 16 weeks and a performance status of
< 2 ECOG scale

- Previous adjuvant chemotherapy with Irinotecan, Oxaliplatin and/or 5-FU based
regimen. Patients who relapse within the first 6 months after the completion of
adjuvant treatment are not eligible for the study.

- Patients must have adequate bone marrow function (defined as peripheral absolute
granulocyte count of > 2.000/µL, and platelet count of > 100.000/µL), adequate liver
function (bilirubin < 1,5 mg/dl), and adequate renal function (creatinine < 1,5 mg/dl

- Patients must be able to understand the nature of this study and give written
informed consent

Exclusion Criteria:

- Patients with T1N0 carcinoma

- Positive cytology of pleural, or pericardial effusion or patients with any peritoneal
disease diagnosed intra-operatively)

- Biopsy proof of lymph node metastases outside the study field such as
supraclavicular, mediastinal, or para-aortic nodes

- Evidence of metastatic disease to distant organs

- Patients with cardiac disease graded as New York Heart Association Class III or IV,
severe uncontrolled diabetes, hypertension, cerebron-vascular disease, or infection

- Patients with diabetic neuropathy

- Abnormalities of mental status such that either the patient cannot fully comprehend
the therapeutic implications of the protocol or comply with the requirements

- Presence of concurrent or previous malignancies in the past 5 years (except for
resected squamous or basal cell carcinoma of the skin)

- Pregnant women are excluded from study entry due to the teratogenic effects of the
study treatment